MarketVIEW: Acne vaccines - market research report

MarketVIEW: Acne vaccines Add to your bookmarks!

$ 8 995 - September 2012 - by VacZine Analytics Group Of Assay Advantage Ltd - 50

Summary

Table of Contents

View Report

Search Inside

Data Series

Industry

Drug and Medication

Country

Japan
Germany
France
Italy
Spain
Canada
Australia
United States

Keywords

Antibiotic
Vaccine

Acne vulgaris is a common skin condition which is estimated to affect 80% of people at some point between 11 and 30 years of age. The condition ranges from mild to severe with latter more likely to cause scarring and psychological impact such as depression, loss of self esteem and in extreme cases, suicidal ideation. Acne is responsible for a significant number of yearly physician office visits and direct costs for treatments which range from OTC lotions to prescription based antibiotics/retinoids.

An acne vaccine targeting the main causative bacterium P.acnes could have wide utility if it prevents inflammatory outbreaks in individuals suffering from acne. Indeed, the major vaccine manufacturer Sanofi Pasteur has already announced interest in this concept (University of San Diego collaboration) confirming its potential attractiveness.

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of acne vaccines (value/volume) to 2030 in the Western region. The product examines different uptake scenarios of the vaccine in severe and non-severe patient groups at different age range(s). Detailed coverage of latest acne epidemiology is included, also a focus on current treatment pathways, costs and the need for a novel vaccine approach. This product is an essential component of any new internal exercise assessing the potential of new acne vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Contents – Executive presentation (MS PowerPoint based)
Title Page
Contents
Author’s notes
Executive Summary
Commercial model: key outputs
Acne vaccine: available market ($ 000s) to 2030 (severe patients)
Acne vaccine: predicted volume (doses 000s) to 2030 (severe patients)
Acne vaccine: available market ($ 000s) to 2030 per country (severe patients)
Acne vaccine: available market ($ 000s) to 2030 (all patients)
Acne vaccine: predicted volume (doses 000s) to 2030 (all patients)
Acne vaccine: available market ($ 000s) to 2030 (BASE SCENARIO)
Acne vaccine: predicted volume (doses 000s) to 2030 (BASE SCENARIO)
Acne Vulgaris: disease background and epidemiology
Acne: brief disease background
Acne: clinical types
Acne: global epidemiology
Acne: adult acne statistics
Acne: impact of the disease
Acne: treatment pathway
Acne: treatment overview
Acne: treatment options
Acne: effectiveness of treatment in mild and moderate cases
Acne: effectiveness of treatment in severe cases
Acne: cost of treatment
Acne: cost of treatment in the US
Acne vaccine; target product profile (TPP)
The role of an acne vaccine
Current status of the vaccine
Pipeline summary
Addressable vaccine populations
Acne vaccine forecast model
Forecast vaccine population flow
Acne vaccine: target product profile
Commercial model assumptions
Detailed commercial model assumptions by country (LO uptake)
Detailed commercial model assumptions by country (BASE uptake)
Acne vaccine: other target populations
Bibliography
Disclaimer
About VacZine Analytics
PAGES: ~50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model(s) (MS Excel-based)
Note: further models can be included with differing vaccine price scenarios
Title page
TOTAL CHARTS (ALL PATIENTS)
TOTAL CHARTS (severe only)
BASE (severe versus non-severe)
CHARTS – VAL HIGH (severe only)
CHARTS – VAL BASE (severe only)
CHARTS – VAL LOW (severe only)
CHARTS – VOL HIGH (severe only)
CHARTS – VOL BASE (severe only)
CHARTS – VOL LOW (severe only)
VALUE SUMMARY (severe only)
VOLUME SUMMARY (severe only)
VALUE SUMMARY (ALL PATIENTS)
VOLUME SUMMARY (ALL PATIENTS)
Country worksheets =>>
US
CANADA
UK
FRANCE
GERMANY
ITALY
SPAIN
AUSTRALIA
JAPAN
Assumptions
Worksheets = 44 per model

Vaccine in Japan